论文部分内容阅读
目的:观察人尿激肽原酶治疗急性脑梗死的近期疗效和安全性。方法:应用人尿激肽原酶0.15 PNAU·d~(-1)×7 d。治疗45例急性脑梗死患者,比较治疗前后NIHSS评分、mRS评分,并观察治疗期间不良反应。结果:①治疗前、治疗7d后患者NIHSS评分、mRS评分明显改善;②2例出现血压明显下降。结论:人尿激肽原酶治疗急性脑梗死疗效明显;安全性较高;在用药期间需注意观察血压的变化。
Objective: To observe the short-term efficacy and safety of human kininogenase in the treatment of acute cerebral infarction. Methods: The human urine kininogenase 0.15 PNAU · d ~ (-1) × 7 d was used. Treatment of 45 patients with acute cerebral infarction, NIHSS score before and after treatment, mRS score, and observed during treatment adverse reactions. Results: ① Before treatment, the NIHSS score and mRS score improved significantly after treatment for 7 days; ② The blood pressure decreased obviously in 2 cases. Conclusion: Human kallikrein treatment of acute cerebral infarction obvious effect; safety is high; during the medication should be noted that changes in blood pressure.